Jane Street Group LLC raised its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report) by 33.3% in the third quarter, HoldingsChannel reports. The firm owned 35,677 shares of the company’s stock after buying an additional 8,918 shares during the quarter. Jane Street Group LLC’s holdings in Lexeo Therapeutics were worth $323,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics during the 3rd quarter worth $67,000. MetLife Investment Management LLC boosted its stake in shares of Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares during the last quarter. Rhumbline Advisers grew its position in shares of Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after acquiring an additional 3,627 shares during the period. Finally, PDT Partners LLC purchased a new stake in shares of Lexeo Therapeutics in the 3rd quarter worth $241,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.
Lexeo Therapeutics Stock Performance
NASDAQ:LXEO opened at $6.82 on Friday. The stock has a 50-day moving average price of $7.15 and a 200 day moving average price of $9.97. The stock has a market capitalization of $225.51 million, a P/E ratio of -2.16 and a beta of 3.08. Lexeo Therapeutics, Inc. has a 12-month low of $5.77 and a 12-month high of $22.33. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on LXEO
Lexeo Therapeutics Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Featured Stories
- Five stocks we like better than Lexeo Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report).
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.